News Headlines

Display #
Title
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
OvaScience Slashes Workforce, Replaces CEO
BIO2017: Biotech Dealmaking Will Be Robust in 2017, But Remain Below 2015 Highs
Novartis heart drug success opens up new care option
Senate Republicans reveal Obamacare replacement bill with tough debate expected
Mylan shareholders vote against executive pay, re-elect board
U.S. Supreme Court ruling threatens massive talc litigation against J&J
The made-in-Italy fast-track acceleration program dedicated to projects in life science
After weeks of secrecy, U.S. Senate to unveil healthcare bill
Novartis AG Rejects Trump’s Proposition to Create More U.S Jobs
Drugmaker Mylan gets boost from unlikely source: coal
U.S. FDA moves to prevent Pharma from ‘gaming’ generic drug system
GSK presents positive revaccination study results
Missouri AG sues opioid manufacturers
Vaccine that lowers cholesterol offers hope of immunizing against cardiovascular disease
Bayer Puts Down More Roots in Massachusetts With New Life Science Center
Scientists find new biomarker to guide cancer immunotherapy
The Piano Starts Softly and Slowly Builds …
FDA approves antibiotic for serious skin infections
Merck Ventures creates new immuno-oncology company iOnctura
Novartis’ Next-Generation Eye Drug Works With Fewer Injections Than Rivals
Parexel Sold to Investment Firm in $5 Billion Deal
A Look at the 5 Most Profitable Biopharma Companies
FDA Approves Cotempla XR-ODT For ADHD
Worldwide drug sale forecasts fall as pricing pressures mount
Coconut oil has more ‘bad’ fat than beef and butter: heart doctors
Adamis wins U.S. approval to sell EpiPen rival
J&J Completes Acquisition of Actelion
New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
Sonar Products, Stratus Pharma Ordered to Cease Operations